Drug Trial News

RSS

Innovative ALS study receives $22 million grant for experimental drug

Mayo Clinic in Florida has received a grant from the National Institute of Neurological Disorders and Stroke (NIDS) to begin an innovative study that will provide hundreds of patients with amyotrophic lateral sclerosis (ALS) access to the experimental drug ibudilast over six months.

24 Sep 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

From Johnson & Johnson 24 Sep 2024

New model identifies cancer patients at high risk for ER visits during clinical trials

Investigators from the SWOG Cancer Research Network have developed and validated a risk prediction model for identifying which patients with advanced cancer who are enrolled to clinical trials are at highest risk for unplanned emergency room (ER) visits and hospital stays.

23 Sep 2024

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

19 Sep 2024

Adaptive platform trial tests multiple treatments for traumatic brain injury

Traumatic brain injury (TBI) results in close to 70,000 deaths in the United States every year, and it is the cause of long-term physical, cognitive and mental disability in 5 million Americans. But despite three decades of work, treatments are sorely lacking.

19 Sep 2024

Drug breakthrough provides new hope for cancer patients with cachexia

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.

19 Sep 2024

Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and The University of Texas M.D. Anderson Cancer Center, have reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.

19 Sep 2024

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

19 Sep 2024

Cancer drug shows promise for treating rare bleeding disorder

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.

19 Sep 2024

Clinical trial finds pomalidomide effective for treating rare bleeding disorder

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that affects 1 in 5,000 people worldwide.

18 Sep 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

Combination immunotherapy yields 10-year survival for metastatic melanoma patients

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues.

16 Sep 2024

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

A double-blind randomized phase 3 clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition of high-dose vitamin D3 to standard treatment for patients with untreated metastatic colorectal cancer.

16 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

New drug shows strong activity against brain metastases in HER2-positive breast cancer

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.

13 Sep 2024

Semaglutide and tirzepatide significantly improve weight loss and glycemic control in type 1 diabetes

Semaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) has found.

13 Sep 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

13 Sep 2024

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

13 Sep 2024

Previous
1
...
20
21
22
23
24
25
26
...
1162
Next

Drug Trial News

Innovative ALS study receives $22 million grant for experimental drug

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

New model identifies cancer patients at high risk for ER visits during clinical trials

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Adaptive platform trial tests multiple treatments for traumatic brain injury

Drug breakthrough provides new hope for cancer patients with cachexia

Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

Cancer drug shows promise for treating rare bleeding disorder

Clinical trial finds pomalidomide effective for treating rare bleeding disorder

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

Ohio State's novel DHODH inhibitor enters first human trials

Combination immunotherapy yields 10-year survival for metastatic melanoma patients

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

New cancer drug shows encouraging results in Phase I/II trial

New drug shows strong activity against brain metastases in HER2-positive breast cancer

Semaglutide and tirzepatide significantly improve weight loss and glycemic control in type 1 diabetes

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News